Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 43,000 shares, a growth of 26.8% from the October 15th total of 33,900 shares. Currently, 0.2% of the company's shares are sold short. Based on an average daily volume of 33,400 shares, the short-interest ratio is presently 1.3 days.
Hedge Funds Weigh In On Theratechnologies
A hedge fund recently raised its stake in Theratechnologies stock. Cyndeo Wealth Partners LLC lifted its holdings in Theratechnologies Inc. (NASDAQ:THTX - Free Report) by 26.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 131,311 shares of the company's stock after acquiring an additional 27,191 shares during the period. Cyndeo Wealth Partners LLC owned approximately 0.29% of Theratechnologies worth $163,000 as of its most recent SEC filing.
Theratechnologies Stock Performance
Shares of Theratechnologies stock traded down $0.01 during trading hours on Friday, hitting $1.20. The company's stock had a trading volume of 1,526 shares, compared to its average volume of 44,168. The firm has a fifty day moving average of $1.25 and a 200-day moving average of $1.31. The stock has a market cap of $55.18 million, a price-to-earnings ratio of -12.10 and a beta of 1.41. Theratechnologies has a twelve month low of $1.08 and a twelve month high of $2.58.
Theratechnologies (NASDAQ:THTX - Get Free Report) last announced its earnings results on Thursday, October 10th. The company reported $0.06 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.03. The business had revenue of $22.60 million during the quarter. During the same quarter last year, the firm earned ($0.03) earnings per share. On average, sell-side analysts expect that Theratechnologies will post 0.03 earnings per share for the current fiscal year.
About Theratechnologies
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
See Also
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
